- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06337084
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
Open Label Pilot Study Evaluating Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
The goal of this study is to test a new PET imaging agent in patients with solid tumors. This tracer is made of a radioactively-labeled monoclonal antibody MNPR-101, and can show where tumors are present in the body using a PET-scan. The investigators will investigate if the new imaging agent correctly shows all tumor lesions. In the future, this method may be useful to help predict who will benefit from certain therapies.
Participants will be injected with the radioactive tracer once. After injection, participants will undergo 3 PET-scans. Each PET-scan will take a maximum of 30 minutes. The PET-scans are on separate days within 10 days after injection of the tracer (e.g., 2 hours after injection plus 3-5 days and 7-10 days after injection). Furthermore, the investigators will take blood samples 6 times (5 mL each). Blood pharmacokinetics (PK) will be measured on Day 1 at 10 min, 1h, 2h, once on Days 3-5, and once on Days 7-10.
The amount of radioactivity injected will range between 37-74 MBq (±10%).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label pilot study to evaluate MNPR-101-DFO*-89Zr with Positron Emission Tomography/Computed Tomography (PET/CT) imaging in patients with solid tumor cancers: bladder/urothelial, triple-negative breast, lung, colorectal, gastric, ovarian, and pancreatic cancers.
Patients will be recruited from a single center with state-of-the-art PET/CT imaging equipment.
The study involves a single administration of MNPR-101-DFO*-89Zr to all participating patients. Imaging will be performed 2 hours after administration and on two additional days - once between days 3-5 and once between days 7-10.
The final study visit will occur 30 days after dosing.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Director Clinical Operations
- Phone Number: 847-724-2466
- Email: monitoring@monopartx.com
Study Locations
-
-
Victoria
-
North Melbourne, Victoria, Australia, 3051
- Recruiting
- Melbourne Theranostic Innovation Centre (MTIC)
-
Contact:
- Referral Coordinator
- Phone Number: 03 9454 5800
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically and/or cytologically confirmed solid tumor cancer
- Age ≥18 years
- Measurable disease ≥ 1 cm on prior 18F-FDG PET/CT scan
- Ability to understand and willingness to sign a written informed consent document
- A prior standard of care 18F-FDG PET/CT scan within past 60 days
- Tumor sample available for IHC testing to demonstrate uPAR expression.
- Females of childbearing potential must have a negative serum pregnancy test at time of screening and a negative urine pregnancy test on Day 1 prior to study drug administration if screening is >7 days prior to Day 1. A rapid serum pregnancy test result performed as standard of care will be accepted if available.
- Both males and females must agree to use highly effective contraceptive precautions if conception is possible during the dosing period and up to 1 month after dosing
- Female patients who are lactating must agree to discontinue breastfeeding prior to the dose of study drug and must refrain from breastfeeding for 1 month following the last dose of study drug
Exclusion Criteria:
- Chemotherapy, radiotherapy (other than short cycle of palliative radiotherapy), or immunotherapy within 14 days prior to administration of MNPR-101-DFO-89Zr, or continuing adverse effects (> grade 1, excluding alopecia, anorexia, fatigue, and neuropathy) from such therapy (Common Terminology Criteria for Adverse Events [CTCAE] version 5.0)
- Prior treatment with any radiopharmaceutical or investigational agents within 4 weeks or 5 half-lives, whichever is longer, prior to administration of the first dose of MNPR-101-DFO-89Zr
- Significantly abnormal laboratory values, particularly: platelets <75K/mcL; ANC <1.0 K/mcL; AST/ALT >2.5 x ULN; Bilirubin >1.5 x ULN (institutional upper limits of normal); and Serum creatinine ≥1.5 mg/dL or estimated creatinine clearance ≤60 mL/min (Cockcroft and Gault)
- Other serious, non-malignant diseases that may interfere (e.g., renal, hepatic, or hematologic) with the objectives of the study, safety, or compliance, as judged by the investigator
- Cognitive impairment or contraindications that may compromise the ability to give informed consent or comply with the requirements of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MNPR-101-DFO*-89Zr
Participants receive a single injection of MNPR-101-DFO*-89Zr on Day 1 with injected activity between 37-74 MBq (±10%).
|
a single injection of MNPR-101-DFO*-89Zr on Day 1 with injected activity between 37-74 MBq (±10%).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
assess dosimetry and biodistribution of product
Time Frame: Day 1 (10 min, 1h, 2h), Days 3-5, and Days 7-10 days post injection
|
Calculate the biodistribution and radiation dose to major organs for each patient
|
Day 1 (10 min, 1h, 2h), Days 3-5, and Days 7-10 days post injection
|
assess tumor Standard Uptake Values (SUV) of product
Time Frame: Day 1 (10 min, 1h, 2h), Days 3-5, and Days 7-10 days post injection
|
Assess concentration of product in tumors at each timepoint for each patient
|
Day 1 (10 min, 1h, 2h), Days 3-5, and Days 7-10 days post injection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
assess pharmacokinetics (PK) levels of product
Time Frame: Day 1 (10 min, 1h, 2h), Days 3-5, and Days 7-10 days post injection
|
Assess amount of product in blood and serum based upon radioactivity measurements at each timepoint for each patient
|
Day 1 (10 min, 1h, 2h), Days 3-5, and Days 7-10 days post injection
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
assess tumor uptake to background and tumor uptake to liver ratios of product
Time Frame: Day 1 (10 min, 1h, 2h), Days 3-5, and Days 7-10 days post injection
|
Assess concentration of product in liver and skeletal muscle against tumor(s) uptake at each timepoint for each patient
|
Day 1 (10 min, 1h, 2h), Days 3-5, and Days 7-10 days post injection
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Prof. Rod Hicks, MD, Melbourne Theranostic Innovation Centre (MTIC)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MNPR-101-D001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedGastric Cancer | Gastric NeoplasmsUnited States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
Clinical Trials on Diagnostic Test: MNPR-101-DFO*-89Zr PET Scan
-
Amsterdam UMC, location VUmcAstraZenecaRecruitingBreast Cancer | Gastric Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric CancerNetherlands
-
Aplagon OyTRACER Europe BVRecruitingPeripheral Arterial Occlusive Disease | Critical Limb IschemiaNetherlands
-
Robert Flavell, MD, PhDUnited States Department of Defense; Fortis Therapeutics, Inc.RecruitingProstate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
First Affiliated Hospital of Fujian Medical UniversityRecruitingProstate Cancer | Positron-Emission TomographyChina
-
National Cancer Institute (NCI)RecruitingMalignant Glioma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditionsUnited States, Puerto Rico, Australia, Canada